2. Search Result
Search Result
Results for "

lateral

" in MedChemExpress (MCE) Product Catalog:

69

Inhibitors & Agonists

2

Screening Libraries

1

Fluorescent Dye

2

Biochemical Assay Reagents

6

Peptides

2

Inhibitory Antibodies

10

Natural
Products

2

Recombinant Proteins

1

Antibodies

7

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-160115
    TDP-43 degrader-1

    		Others Neurological Disease
    TDP-43 degrader-1 (example 3) reduces the TDP-43 aggregation that can be in the research of Amyotrophic lateral sclerosis and? Alzheimer's disease .
    TDP-43 degrader-1
  • HY-105005
    Crisdesalazine

    AAD-2004

    		 Prostaglandin Receptor Neurological Disease
    Crisdesalazine (AAD-2004) is an anti-inflammatory agent that simultaneously blocks inflammation mediated by free radicals and prostaglandin E2 (PGE2). Crisdesalazine (AAD-2004) can be used to study neurodegeneration in amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases .
    Crisdesalazine
  • HY-153019
    NUCC-0000323

    		SOD Neurological Disease
    NUCC-0000323 is a potent superoxide dismutase 1 (SOD1) inhibitor. NUCC-0000323 inhibits SOD1 expression. NUCC-0000323 can be used in research of amyotrophic lateral sclerosis (ALS) .
    NUCC-0000323
  • HY-132845
    Utreloxastat

    PTC857

    		 α-synuclein Cytochrome P450 Ferroptosis Lipoxygenase Neurological Disease
    Utreloxastat (PTC857) is an orally active 15-lipoxygenase inhibitor that can cross the blood-brain barrier. Utreloxastat is a weak inhibitor of CYP1A2 and 2B6 with an IC50 > 5.3 μM. Utreloxastat reduces oxidative stress and inhibits the consumption of reduced glutathione and ferroptosis. Utreloxastat can be used in the study of neurodegenerative diseases characterized by high levels of oxidative stress and mitochondrial pathology, such as amyotrophic lateral sclerosisc .
    Utreloxastat
  • HY-W015546
    β-N-methylamino-L-alanine hydrochloride
    1 Publications Verification

    BMAA hydrochloride

    		 Bacterial Neurological Disease
    β-N-methylamino-L-alanine hydrochloride (BMAA hydrochloride) is a neurotoxin produced by cyanobacteria. β-N-methylamino-L-alanine hydrochloride could cause amyotrophic lateral sclerosis (ALS) and possibly other neurodegenerative diseases .
    β-N-methylamino-L-alanine hydrochloride
  • HY-134477
    NF-κΒ activator 2
    3 Publications Verification

    		 NF-κB Neurological Disease
    NF-κΒ activator 2 is a potent and orally active NF-ҡB activator, with an EC50 of 1.58 μM. NF-κΒ activator 2 induces SOD2 through increasing NF-ҡB expression and activation. NF-κΒ activator 2 can be used for the research of amyotrophic lateral sclerosis (ALS) .
    NF-κΒ activator 2
  • HY-145712
    ElteN378

    		FKBP Cancer
    ElteN378 is an inhibitors of FKBP12e. ElteN378 can be used in study Alzheimer disease, Parkinson disease, Amyotrophic Lateral Sclerosis, proliferation disorders and cancer .
    ElteN378
  • HY-132580A
    Tofersen sodium

    BIIB067 sodium; ISIS-SOD1Rx sodium

    		 DNA/RNA Synthesis Neurological Disease
    Tofersen sodium is an antisense oligonucleotide that mediates RNase H-dependent degradation of superoxide dismutase 1 (SOD1) mRNA to reduce the synthesis of SOD1 protein. Tofersen sodium can be used for the research of amyotrophic lateral sclerosis (ALS) .
    Tofersen sodium
  • HY-120570
    WN1316

    		Others Neurological Disease
    WN1316 is an oral active antioxidant agent. WN1316 shows neuroprotectant activity and can be used for study of amyotrophic lateral sclerosis .
    WN1316
  • HY-132580
    Tofersen

    BIIB067; ISIS-SOD1Rx

    		 DNA/RNA Synthesis Neurological Disease
    Tofersen (BIIB067) is an antisense oligonucleotide that mediates RNase H-dependent degradation of superoxide dismutase 1 (SOD1) mRNA to reduce the synthesis of SOD1 protein. Tofersen can be used for the research of amyotrophic lateral sclerosis (ALS) .
    Tofersen
  • HY-D1378
    C-Laurdan

    		Fluorescent Dye Others
    C-Laurdan is a fluorescent probe for imaging lipid rafts with environmentally sensitive fluorescence. C-Laurdan exhibits strong photostability under two-photon excitation and can be used for single and two-photon fluorescence imaging to detect lipid membrane properties such as membrane lateral organisation, various membrane-associated processes, etc .
    C-Laurdan
  • HY-146530
    c-ABL-IN-4

    		Others Neurological Disease Cancer
    c-ABL-IN-4 is a potent inhibitor of c-Abl. Activation of c-Abl has been implicated in various diseases, notably cancer. c-ABL-IN-4 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2021048567A1, compound 54) .
    c-ABL-IN-4
  • HY-146528
    c-ABL-IN-3

    		Others Neurological Disease Cancer
    c-ABL-IN-3 is a potent inhibitor of c-Abl. Activation of c-Abl has been implicated in various diseases, notably cancer. c-ABL-IN-3 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2021048567A1, compound 50) .
    c-ABL-IN-3
  • HY-169904
    AKV-9

    		SOD Neurological Disease
    AKV-9 is the inhibitor for mutated Cu/Zn superoxide dismutase (SOD1), that inhibits SOD1-induced protein aggregation and exhibits protective efficacy against SOD1-induced cytotoxicity in PC-12 with an EC50 of 0.3 μM. AKV-9 ameliorates amyotrophic lateral sclerosis in mouse models and extends their lifespan .
    AKV-9
  • HY-148629
    GDC-0134

    		JNK Neurological Disease
    GDC-0134 is a potent, selective, orally active, brain-penetrant dual leucine zipper kinase (DLK) inhibitor. GDC-0134 blocks DLK activity in cellular assays and in animal models of neuronal injury. GDC-0134 can be used for the study of amyotrophic lateral sclerosis (ALS) .
    GDC-0134
  • HY-161875
    NAT1-IN-1

    		Histone Acetyltransferase Metabolic Disease Cancer
    NAT1-IN-1 (compound 350) is a potent N-acetyltransferase 1 (NAT1)-targeted inhibitor, with an IC50 of 44 nM. NAT1-IN-1 can be used for the research of hypermetabolic diseases such as amyotrophic lateral sclerosis, cancer cachexia, and sepsis .
    NAT1-IN-1
  • HY-P3414
    Proteasome-activating peptide 1

    		Proteasome Neurological Disease
    Proteasome-activating peptide 1 is a peptide, which increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 prevents protein aggregation in a cellular model of amyotrophic lateral sclerosis .
    Proteasome-activating peptide 1
  • HY-P99008
    Atibuclimab
    1 Publications Verification

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    Atibuclimab, is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab can be used for the research of amyotrophic lateral sclerosis . Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist .
    Atibuclimab
  • HY-119274
    BN-82451 dihydrochloride

    		Others Neurological Disease
    BN-82451 dihydrochloride, an orally active and CNS-penetrated antioxidant and a multitargeting neuroprotective agent, exert a significant protection in experimental animal models mimicking aspects of cerebral ischemia, Parkinson disease, Huntington disease, and more particularly amyotrophic lateral sclerosis .
    BN-82451 dihydrochloride
  • HY-146527
    c-ABL-IN-2

    		Bcr-Abl Neurological Disease Cancer
    c-ABL-IN-2 is a potent inhibitor of c-Abl. Activation of c-Abl has been implicated in various diseases, notably cancer. c-ABL-IN-2 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2020260871A1, compound 25) . c-ABL-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    c-ABL-IN-2
  • HY-N2707
    6-Deoxyjacareubin

    		Reactive Oxygen Species Neurological Disease Cancer
    6-Deoxyjacareubin is a natural xanthone, that can be isolated from the leaves of Vismia latifolia. 6-Deoxyjacareubin protects against non-apoptotic cell death by inhibiting ROS production. 6-Deoxyjacareubin ameliorates neurodegeneration in a mouse model of familial amyotrophic lateral sclerosis (ALS) .
    6-Deoxyjacareubin
  • HY-118858
    UCPH-102

    		EAAT Neurological Disease Cancer
    UCPH-102 is a highly selective EAAT1 inhibitor with an IC50 of 0.43 µM. UCPH-102 exhibits a specific anti-proliferative effect on T-ALL cells. UCPH-102 also shows good blood-brain permeability, which can be used in studies of amyotrophic lateral sclerosis, Alzheimer’s disease, chronic pain and obsessive compulsive disorder .
    UCPH-102
  • HY-147410
    Ulefnersen

    ION-363

    		 DNA/RNA Synthesis Others Neurological Disease
    Ulefnersen (ION363) is an Antisense Oligonucleotide (ASO) directed against the 6th intron of the fused-in sarcoma (FUS) transcript to silence FUS in a non-allele-specific manner. Ulefnersen can reduce postnatal levels of FUS protein in the brain and spinal cord in disease-relevant mouse model of ALS-FUS , delaying motor neuron degeneration. Ulefnersen can be used in the research of Amyotrophic Lateral Sclerosis (ALS) .
    Ulefnersen
  • HY-147410A
    Ulefnersen sodium

    ION-363 sodium

    		 Others DNA/RNA Synthesis Neurological Disease
    Ulefnersen sodium (ION363) is an Antisense Oligonucleotide (ASO) directed against the 6th intron of the fused-in sarcoma (FUS) transcript to silence FUS in a non-allele-specific manner. Ulefnersen sodium can reduce postnatal levels of FUS protein in the brain and spinal cord in disease-relevant mouse model of ALS-FUS , delaying motor neuron degeneration. Ulefnersen sodium can be used in the research of Amyotrophic Lateral Sclerosis (ALS) .
    Ulefnersen sodium
  • HY-123982
    SOD1-Derlin-1 inhibitor-2

    		Others Neurological Disease
    SOD1-Derlin-1 inhibitor-2 (compound 56-59) is an inhibitor of SOD1-Derlin-1 interaction. SOD1-Derlin-1 inhibitor-2 attenuates the interactions between Derlin-1 and SOD1 mut. SOD1-Derlin-1 inhibitor-2 can be used for the research of amyotrophic lateral sclerosis (ALS) .
    SOD1-Derlin-1 inhibitor-2
  • HY-N10579
    Chrexanthomycin C

    		DNA/RNA Synthesis Neurological Disease
    Chrexanthomycin C is an orally active marine natural product with remarkable bioactivities. Chrexanthomycin C has binding affinity for DNA (G4C2) 4 G4 with a Kd value of 2.8 mM. Chrexanthomycin C can be used for the research of neurodegenerative disease such as amyotrophic lateral sclerosis (ALS) .
    Chrexanthomycin C
  • HY-P3414A
    Proteasome-activating peptide 1 TFA
    1 Publications Verification

    		 Proteasome Neurological Disease
    Proteasome-activating peptide 1 TFA is a peptide and a potent proteasome activator. Proteasome-activating peptide 1 TFA increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 TFA prevents protein aggregation in a cellular model of amyotrophic lateral sclerosis .
    Proteasome-activating peptide 1 TFA
  • HY-170409
    BNN27

    		Trk Receptor Apoptosis Neurological Disease Inflammation/Immunology
    BNN27 is the agonist for TrkA receptor and p75NTR receptor, that exhibits neurotrophic and anti-apoptotic effects. BNN27 increases the levels of glutamate, GABA, and glutamine in the rat hippocampus and prefrontal cortex, improves glutamate turnover. BNN27 exhibits neuroprotective efficacy in mouse amyotrophic lateral sclerosis (ALS) model, exhibits anti-inflammatory efficacy in experimental autoimmune encephalomyelitis (EAE) model, exhibits retinal protective efficacy in rat diabete models. BNN27 is blood-brain barrier penetrable .
    BNN27
  • HY-138131
    SOD1-Derlin-1 inhibitor-1

    		Others Neurological Disease
    SOD1-Derlin-1 inhibitor-1 (compound 56-20) is an inhibitor of SOD1-Derlin-1 interaction. SOD1-Derlin-1 inhibitor-1 inhibits SOD1 G93A-Derlin-1 complex with an IC50 value of 7.11 μM. SOD1-Derlin-1 inhibitor-1 can be used for the research of amyotrophic lateral sclerosis .
    SOD1-Derlin-1 inhibitor-1
  • HY-N1974
    Fuziline

    15α-Hydroxyneoline

    		 Others Cardiovascular Disease
    Fuziline is a alkaloid isolated from the lateral roots of Aconitum carmichaelii .
    Fuziline
  • HY-114898
    ML404

    		Others Cardiovascular Disease Neurological Disease
    ML404 (Compound 38) is an inhibitor of the mitochondrial permeability transition pore (mtPTP), which can suppress mitochondrial swelling (EC50=4.9 nM) and only disrupts mitochondrial coupling (an adverse effect) at concentrations > 100 μM. ML404 can be utilized in research related to multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), muscular dystrophies (MD), myocardial infarction, and stroke .
    ML404
  • HY-P10627
    SOD1 (147-153) human

    		Amyloid-β Neurological Disease
    SOD1 (147-153) human is a peptide fragment of Cu/Zn superoxide dismutase (SOD1) with a high propensity to form amyloid fibrils. SOD1 (147-153) human may trigger the aggregation of full-length SOD1 and is a common molecular determinant of familial amyotrophic lateral sclerosis (fALS) and sporadic amyotrophic lateral sclerosis (sALS) .
    SOD1 (147-153) human
  • HY-N1974R
    Fuziline (Standard)

    		Others Cardiovascular Disease
    Fuziline (Standard) is the analytical standard of Fuziline. This product is intended for research and analytical applications. Fuziline is a alkaloid isolated from the lateral roots of Aconitum carmichaelii .
    Fuziline (Standard)
  • HY-N11021
    Feruloyl tyramine

    		Others Others
    Feruloyl tyramine, an amide compound, can be isolated from ethanol extract of hemp seed. Feruloyl tyramine injected into the lateral ventricle caused hypothermia and dyskinesia in mice .
    Feruloyl tyramine
  • HY-125999
    EPI-589

    		Others Neurological Disease
    EPI-589, a quinone derivative, is a safe and well tolerated oxidoreductase?enzyme inhibitor. EPI-589 has the potential for the treatment of amyotrophic lateral sclerosis (ALS) .
    EPI-589
  • HY-148901
    CMB-087229

    		SOD Neurological Disease
    CMB-087229 is a mutant superoxide dismutase 1 (SOD1) protein aggregation inhibitor with IC50 of 67 nM, which can be used in the research of amyotrophic lateral sclerosis .
    CMB-087229
  • HY-P5741
    IPL344

    		Akt Inflammation/Immunology
    IPL344 protects cells of various types from pro-apoptotic pressures and activates the Akt signaling system. IPL344 can be used for research of amyotrophic lateral sclerosis (ALS) .
    IPL344
  • HY-113726
    Nerisopam

    GYKI52322; EGIS-6775

    		 GABA Receptor Neurological Disease
    Nerisopam is an orally active gamma-aminobutyric acid (GABA) receptor agonist. Nerisopam is an anxiolytic and antipsychotic homophthalazine. Nerisopam induces rapid, intense expression of Fos-like immunoreactivity in the rostral, dorsomedial and lateral parts of the striatum in the rat .
    Nerisopam
  • HY-141878
    di-Ellipticine-RIBOTAC

    		PROTACs Neurological Disease
    di-Ellipticine-RIBOTAC is a dual-function small molecule that reduces c9ALS/FTD r(G4C2) repeat expansion in vitro and in vivo amyotrophic lateral sclerosis (ALS ) models.
    di-Ellipticine-RIBOTAC
  • HY-169485
    Aspinolide B

    		Endogenous Metabolite Others
    Aspinolide B is a pentaketide and a 10-membered lactone with plant growth regulatory activity, which can be extracted from Aspergillus ochraceus. Aspinolide B promotes the growth of lateral roots in S. lycopersicum and can be utilized in related research .
    Aspinolide B
  • HY-112412
    PDGFR Tyrosine Kinase Inhibitor III

    PDGF Receptor Tyrosine Kinase Inhibitor III

    		 PDGFR Neurological Disease
    PDGFR Tyrosine Kinase Inhibitor III (PDGF Receptor Tyrosine Kinase Inhibitor III), a multikinase inhibitor, inhibits PDGFR, EGFR, FGFR, PKA, and PKC, respectively. PDGFR Tyrosine Kinase Inhibitor III can be used for the research of amyotrophic lateral sclerosis .
    PDGFR Tyrosine Kinase Inhibitor III
  • HY-162303
    C175-0062

    		Monoamine Oxidase Neurological Disease
    C175-0062 is a monoamine oxidase B (MAO-B) inhibitor. C175-0062 can be used for the research of neurodegenerative disorders, including Parkinson's disease (PD), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS) .
    C175-0062
  • HY-18573
    Naxillin

    		Others Others
    Naxillin is a non-auxin-like molecule, which can promote the lateral root branching in the basal meristem of the root, through the conversion of the auxin precursor indole-3-butyric acid (IBA) to the active auxin indole-3-acetic acid (IAA) .
    Naxillin
  • HY-W127737
    Methylcobalamin hydrate

    Mecobalamin hydrate

    		 Biochemical Assay Reagents Others
    Methylcobalamin Hydrate is a coenzyme required for methionine biosynthesis. Vitamins (hematopoiesis). It acts as a histamine receptor, Alzheimer study. Methylcobalamin is also used in the research of peripheral neuropathy, diabetic neuropathy, and as an initial research for amyotrophic lateral sclerosis. It can be used to prevent or research pathologies caused by vitamin B12 deficiency, such as pernicious anemia.
    Methylcobalamin hydrate
  • HY-N13302
    Cedrene

    		Others Others
    Cedrene regulates auxin transport and signal transduction in Arabidopsis, and thus stimulates the plants root development. Cedrene affects the Arabidopsis roots morphology by increasing the lateral roots, promoting the elongation of primary roots, affecting the expression of the auxin response gene DR5 and auxin transporters such as PIN2 and PIN3 .
    Cedrene
  • HY-W011978
    N-Acetyl-L-tryptophan

    		Endogenous Metabolite Mitochondrial Metabolism Neurokinin Receptor Caspase Interleukin Related Neurological Disease Inflammation/Immunology
    N-Acetyl-L-tryptophan is an antagonist of the neurokinin-1 receptor (NK-1R), disrupting the binding of substance P (SP) to NK-1R. This action provides neuroprotective effects, improving memory deficits and motor impairments. N-Acetyl-L-tryptophan is also an inhibitor of cytochrome c (Cytochrome c), and it exerts antioxidant and anti-inflammatory effects by inhibiting the expression of IL-1β and the activation of caspase-1. N-Acetyl-L-tryptophan holds promise for research in neurodegenerative and inflammatory diseases .
    N-Acetyl-L-tryptophan
  • HY-148455
    Casein kinase 1δ-IN-3

    		Casein Kinase Neurological Disease
    Casein kinase 1δ-IN-3 (Compound 23a) is a casein kinase 1 delta (CK1d) inhibitor with a pIC50 of 6.5376 M .
    Casein kinase 1δ-IN-3
  • HY-12768B
    Sotuletinib dihydrochloride

    BLZ945 dihydrochloride

    		 c-Fms Neurological Disease Cancer
    Sotuletinib (BLZ945) dihydrochloride is an orally active and blood-brain barrier-permeable CSF1-R-specific inhibitor (IC50=1 nM). Sotuletinib (BLZ945) dihydrochloride induces tumor cell apoptosis and effectively inhibits tumor growth in mouse models. Sotuletinib dihydrochloride can be used in cancer and amyotrophic lateral sclerosis (ALS) research .
    Sotuletinib dihydrochloride
  • HY-144425
    BSc5367

    		NEKs Inflammation/Immunology
    BSc5367 is a potent Nek1 inhibitor with an IC50 of 11.5 nM. NIMA-related protein kinase Nek1 is crucially involved in cell cycle regulation, DNA repair and microtubule regulation and dysfunctions of Nek1 play key roles in amyotrophic lateral sclerosis (ALS), polycystic kidney disease (PKD) and several types of radiotherapy resistant cancer .
    BSc5367
  • HY-114753
    Neboglamine

    CR-2249; XY-2401

    		 iGluR Neurological Disease
    Neboglamine (CR-2249; XY-2401) is a modulator for N-methyl-D-aspartate (NMDA) receptor. Neboglamine increases the levels of fos-like immunoreactivity (FLI)-positive cells in the prefrontal cortex, nucleus accumbens, and lateral septal nucleus in rat models, .restores NMDA (HY-17551) -mediated neurotransmitter release, and inhibits phencyclidine-induced hyperlocomotion .
    Neboglamine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: